Mylan subsidiary Mylan Technologies has received final approval from the US Food and Drug Administration for its abbreviated drug application for its clonidine transdermal system (CTS).

The CTS is approved in the 0.1mg/day, 0.2mg/day and 0.3mg/day strengths for the treatment of hypertension (high blood pressure).

CTS is a generic version of Boehringer Ingelheim’s Catapres-TTS, and had US sales of around $313m for the 12 months ending 31 March 2010, according to IMS Health.